Cargando…
Drug metabolism and pancreatic cancer
Pancreatic cancer remains a fatal disease in the majority of patients. The era of personalized medicine is upon us: customizing therapy according to each patient’s individual cancer. Potentially, therapy can be targeted at individuals who would most likely have a favorable response, making it more e...
Autores principales: | Flores, John Paul E., Diasio, Robert B., Saif, Muhammad Wasif |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198247/ https://www.ncbi.nlm.nih.gov/pubmed/28042238 http://dx.doi.org/10.20524/aog.2016.0074 |
Ejemplares similares
-
Hypokalemia secondary to capecitabine: a hidden toxicity?
por: Saif, Muhammad Wasif, et al.
Publicado: (2007) -
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor
por: Saif, Muhammad Wasif, et al.
Publicado: (2016) -
Genetic factors affecting patient responses to pancreatic cancer treatment
por: Fotopoulos, George, et al.
Publicado: (2016) -
2016 Gastrointestinal Cancers Symposium: update on pancreatic cancer
por: Russo, Suzanne, et al.
Publicado: (2016) -
Pancreatic Tuberculosis or Autoimmune Pancreatitis
por: Salahuddin, Ayesha, et al.
Publicado: (2014)